CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.07B, above the global median of $1.15B
- PositionCurrent ratio is 0.88×, lower than 95% of its Biotechnology peers (median 5.5×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
13.95BCNY2.07B · vs all stocks (USD)
Revenue (TTM)
745.32MCNY110.84M · vs all stocks (USD)
Profit Margin
-123.38%vs Biotechnology peers
Beta
0.5220xvs all stocks
52-Week Change
-20.53%vs all stocks
Market Capitalization
13.95BCNY2.07B · vs all stocks (USD)
Enterprise Value
15.18BCNY2.26B · vs all stocks (USD)
Forward P/E
-31.70xvs Biotechnology peers
Price to Sales (TTM)
18.81xvs Biotechnology peers
Price to Book (MRQ)
117.09xvs Biotechnology peers
Enterprise to Revenue
20.37xvs Biotechnology peers
Enterprise to EBITDA
-24.14xvs Biotechnology peers
Gross Margin
76.15%vs Biotechnology peers
Profit Margin
-123.38%vs Biotechnology peers
Operating Margin
-160.48%vs Biotechnology peers
Return on Assets (TTM)
-11.80%vs Biotechnology peers
Return on Equity (TTM)
-118.88%vs Biotechnology peers
Revenue (TTM)
745.32MCNY110.84M · vs all stocks (USD)
Revenue per Share (TTM)
1.87CNYUpdated Aug 21, 2026Quarterly Revenue Growth
184.90%vs Biotechnology peers
Gross Profit (TTM)
649.14MCNY96.53M · vs all stocks (USD)
EBITDA (TTM)
-628.92MCNY-93.53M · vs all stocks (USD)
Net Income (TTM)
-919.55MCNY-136.75M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
117.42%vs Biotechnology peers
Operating Cash Flow (TTM)
-307.77MCNY-45.77M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-338.81MCNY-50.39M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
183.50MCNYFY2025 · Dec 31, 2025Revenue
662.52MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
64.46MCNYFY2025 · Dec 31, 2025Gross Profit
598.05MCNYFY2025 · Dec 31, 2025Operating Income
-851.23MCNY-126.59M · vs all stocks (USD)
Pre-tax Income
-956.39MCNYFY2025 · Dec 31, 2025Income Tax Expense
15.86MCNYFY2025 · Dec 31, 2025Net Income
-972.26MCNYFY2025 · Dec 31, 2025EBIT
-865.55MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-640.46MCNYFY2025 · Dec 31, 2025Research & Development
976.96MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
184.51MCNYFY2025 · Dec 31, 2025Other Operating Expenses
12.10MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
7.61MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
90.85MCNYFY2025 · Dec 31, 2025EPS (Basic)
-2.43CNYFY2025 · Dec 31, 2025EPS (Diluted)
-2.43CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
398.90MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
398.90MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-972.26MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
2.92MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-891.81MCNYFY2025 · Dec 31, 2025Free Cash Flow
-1.05BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.53BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-972.26MCNYFY2025 · Dec 31, 2025Stock-based Compensation
110.24KCNYFY2025 · Dec 31, 2025Other Non-cash Items
98.11MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-30.30MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
12.52MCNYFY2025 · Dec 31, 2025Capital Expenditures
-157.71MCNYFY2025 · Dec 31, 2025Purchase of Investments
-271.83MCNYFY2025 · Dec 31, 2025Sale of Investments
230.23MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-199.31MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
2.87BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-2.23BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-78.38MCNYFY2025 · Dec 31, 2025Other Financing Charges
234.76MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
791.92MCNYFY2025 · Dec 31, 2025Shares Outstanding
399.60MSharesUpdated Aug 21, 2026Float Shares
216.10MSharesUpdated Aug 21, 2026% Held by Insiders
52.29%vs all stocks
% Held by Institutions
11.51%vs all stocks
Total Cash (MRQ)
1.49BCNY221.44M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.74CNYUpdated Aug 21, 2026Total Debt (MRQ)
3.27BCNY485.60M · vs all stocks (USD)
Total Debt to Equity (MRQ)
11.29xvs Biotechnology peers
Current Ratio (MRQ)
0.8760xvs Biotechnology peers
Book Value per Share (MRQ)
0.2680CNYUpdated Aug 21, 2026Total Assets
4.56BCNY677.50M · vs all stocks (USD)
Total Current Assets
2.04BCNYFY2025 · Dec 31, 2025Total Liabilities
4.02BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.52BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
1.76BCNYFY2025 · Dec 31, 2025Total Current Liabilities
2.26BCNYFY2025 · Dec 31, 2025Cash
1.53BCNYFY2025 · Dec 31, 2025Cash Equivalents
231.29KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.53BCNYFY2025 · Dec 31, 2025Accounts Receivable
99.79MCNYFY2025 · Dec 31, 2025Inventory
187.90MCNYFY2025 · Dec 31, 2025Accounts Payable
197.38MCNYFY2025 · Dec 31, 2025Short-term Debt
1.46BCNYFY2025 · Dec 31, 2025Other Current Liabilities
34.46KCNYFY2025 · Dec 31, 2025Long-term Debt
1.46BCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
229.09MCNYFY2025 · Dec 31, 2025Common Stock (Book)
399.60MCNYFY2025 · Dec 31, 2025Retained Earnings
-5.76BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
533.00MCNY79.26M · vs all stocks (USD)
Treasury Stock
49.99MCNYFY2025 · Dec 31, 202552-Week Low
25.13CNYUpdated Aug 21, 202652-Week High
63.59CNYUpdated Aug 21, 202652-Week Change
-20.53%vs all stocks
Beta
0.5220xvs all stocks
50-Day MA
30.33CNYUpdated Aug 21, 2026200-Day MA
35.65CNYUpdated Aug 21, 2026Avg 10-Day Volume
12.21MSharesUpdated Aug 21, 2026Avg 30-Day Volume
11.64MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-2.31CNYUpdated Aug 21, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.88×, lower than 95% of its Biotechnology peers (median 5.5×)Significant
Current ratio: 0.88Industry median: 5.50Industry P5: 0.97Peers compared: 197
Debt-to-equity is 11.29×, higher than 95% of its Biotechnology peers (median 0.1×)Significant
Debt-to-equity: 11.29Industry median: 0.10Industry P95: 2.96Peers compared: 197
Price-to-book is 117.09×, higher than 95% of its Biotechnology peers (median 5.36×)Significant
Price-to-book: 117.09Industry median: 5.36Industry P95: 37.43Peers compared: 197
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.76Profit Margin: -1.23
Financial Health
Altman Z-Score -0.23: distress zoneCritical
Altman Z-Score: -0.23
Low earnings qualitySignificant
Earnings Quality Score: -0.50
High structural barrier to entryNotable
Barrier to Entry: 22.51
Consistent revenue growth patternNotable
Growth Consistency Score: 1.42
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.07B, above the global median of $1.15BNotable
Market cap (USD): 2,074,710,336.352Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Monte Rosa Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Weigao Blood Purification Products Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kalbe Farma Tbk. PT
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ab&B Bio-Tech Co., Ltd. (JS)
Tier 1ProductionApproval-Gated PipelineRule
Verano Holdings Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Aurinia Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
GemPharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Anhui Anke Biotechnology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Molina Healthcare Inc.
1 interpretationRevenue Growing With Receivables Growing
Hd Hyundai Heavy Industries Co., Ltd.
1 interpretationRevenue Growing With Receivables Growing
Clean Harbors Inc.
1 interpretationRevenue Growing With Receivables Growing